GLP1R and atherosclerosis: While previous studies have assessed cardiovascular outcomes in people with T2D and have largely assessed the older generation of GLP-1 RAs, the present study is among the first to examine cardiovascular outcomes in a large US population with T2D and ASCVD and those treated with the newer generation of OW GLP-1 RAs (eg, dulaglutide, semaglutide).